<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186026</url>
  </required_header>
  <id_info>
    <org_study_id>514-0386/19-3000</org_study_id>
    <nct_id>NCT04186026</nct_id>
  </id_info>
  <brief_title>Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.</brief_title>
  <official_title>Effect of Combination of the Gut Hormones Neurotensin and GLP-1 on Physiological Regulation of Appetite and Food Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurotensin (NT), a gut hormone and neuropeptide, and GLP-1, as well a gut hormone, increases
      in circulation after bariatric surgery in rodents and humans and inhibit food intake in mice.

      Studies in rodents have shown that a GLP-1 receptor agonist and long acting neurotensin
      inhibit food intake.

      This study investigates whether the synergistic anorexic effects of neurotensin and GLP-1
      agonism suggested by animal studies can be translated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will be studied on multiple occasions (4 days) in a randomised and double blinded fashion.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants will not be informed of the nature of the infusion they are administered on any of the study days. The investigator will be provided with an infusion (either isotonic saline with humane serum albumine (HSA) or isotonic saline with HSA + neurotensin or isotonic saline with HSA + GLP-1) prepared by a designated colleague</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ad-libitum food intake</measure>
    <time_frame>120 min</time_frame>
    <description>Neurotensin (NT), saline, GLP-1 and GLP-1+Neurotensin will be infused on four occasions in random order, double blinded. After 2h of infusion an ad libitum meal will be served. When the meal is completed food intake will be determined by weighing the leftovers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appetite and gastrointestinal sensations</measure>
    <time_frame>-60, -30, 0, 30, 60, 90, 120, 150 and 180 min</time_frame>
    <description>Using visual analogue scales (VAS) the effect of infusions and meals will be documented.
Ad libitum meals will also be evaluated using VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Bed-side measurements of plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotensin</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Serum analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Serum analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bile acids</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide YY (PYY)</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics</measure>
    <time_frame>-60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Saline+Saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurotensin+Saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1+Saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurotensin + GLP-1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline + saline</intervention_name>
    <description>Double saline infusion followed by an ad libitum meal</description>
    <arm_group_label>Saline+Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurotensin + saline</intervention_name>
    <description>Neurotensin + saline infusion followed by an ad libitum meal</description>
    <arm_group_label>Neurotensin+Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-1 + saline</intervention_name>
    <description>GLP-1 + saline infusion followed by an ad libitum meal</description>
    <arm_group_label>GLP-1+Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-1 + Neurotensin</intervention_name>
    <description>GLP-1 + Neurotensin infusion followed by an ad libitum meal</description>
    <arm_group_label>Neurotensin + GLP-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Above 18 years of age

          -  Normal hemoglobin concentration

          -  28&lt;BMI&lt;40 kg/m2

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Truncal vagotomy

          -  Resection of intestine (apart from appendectomy)

          -  Tobaccos use

          -  Nephropathy (serum-creatinin&gt;130 micromolar or/and albuminuria)

          -  Liver disease (Alanine transaminase or/and aspartate transaminase&gt;2 times normal
             range.)

          -  Treatment with medication that cannot be paused in 12 hours

          -  Allergy towards latex or plastic

          -  Bleeding disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Birgitte Holst, PhD, Professor</last_name>
    <phone>+4521487699</phone>
    <email>holst@sund.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sten Madsbad, DMsc, Professor</last_name>
    <phone>+4521691911</phone>
    <email>sten.madsbad@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Copenhagen, Department of Biomedical Scienses</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgitte Holst, Professor</last_name>
      <phone>+4521487699</phone>
      <email>holst@sund.ku.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital Hvidovre</name>
      <address>
        <city>Copenhagen</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sten Madsbad, Professor</last_name>
      <phone>+4521691911</phone>
      <email>sten.madsbad@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Sten Madsbad, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Birgitte Holst</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Neurotensin</keyword>
  <keyword>Glucagon like peptide-1 (GLP-1)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

